Drug intelligence / Profile preview

BAY 2501293

Development stage: Preclinical
Lead developer: Bayer
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

BAY 2501293 is a molecular glue, part of a class of compounds termed velcrins, developed by Bayer. It acts by promoting the formation of a complex between phosphodiesterase 3A (PDE3A) and the ribonuclease Schlafen 12 (SLFN12). This molecular glue mechanism activates SLFN12, which then specifically cleaves the leucine tRNA (tRNALeu(TAA)), resulting in the inhibition of protein translation and the induction of apoptosis. BAY 2501293 has shown efficacy in preclinical glioblastoma models, particularly those with high expression of the biomarker pair PDE3A and SLFN12.

Targets

PDE3A (Phosphodiesterase 3A)SLFN12 (Schlafen family member 12)

Beyond the preview

Go deeper on BAY 2501293.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY 2501293.

Explore the full profile